Trial Profile
A Phase III, Multicenter, Randomized, Open Study of SHR3680 Compared to Bicalutamide in the Treatment of Patients With Hormone Sensitive Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Rezvilutamide (Primary) ; Bicalutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms CHART
- Sponsors Jiangsu Hengrui Medicine Co.
- 24 Oct 2023 Results of post-hoc analysis assessing the association between achievement of deep prostate-specific antigen decline with survival outcomes in patients with high-volume mHSPC in the CHART trial, presented at the 48th European Society for Medical Oncology Congress.
- 05 Sep 2022 Primary endpoint has been met (OS), as per Results published in the Lancet Oncology
- 05 Sep 2022 Interim Results evaluating the efficacy and safety of rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy, published in the Lancet Oncology